WHAT IS CLAIMED IS:

1. A compound of structural formula I:

$$\mathbb{R}^{1}$$
 \mathbb{R}^{2} \mathbb{R}^{3} \mathbb{R}^{4} \mathbb{R}^{4} \mathbb{R}^{4} \mathbb{R}^{3} \mathbb{R}^{4} \mathbb{R}^{4}

5

15

(1)

wherein:

R1 is selected from:

- (1) C₁.10alkyl,
- (2) C3-10cycloalkyl,
- 10
- (3) cycloheteroalkyl,
- (4) aryl, and
- (5) lieteroaryl,

wherein alky is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

R² is selected from:

- (1) C3-10cycloalkyl,
- (2) cycloheteroalkyl,
- 20 (3) aryl,
 - (4) heteroaryl,
 - (5) -ORd,
 - (6) -NRCRd, and
 - (7) -CO2Rd,
- wherein each alkyl is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, and cycloheteroalkyl aryl and beteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b.

R3 is selected from:

30

(i) C₁₋₄alkyl,

- (23) -NRCC(O)Rd,
- (24) -OC(O)NRCRd,
- (25) -NRCC(O)ORd,
- (26) -NRCC(O)NRCRd,
- 5 (27) CF3, and
 - (28):-OCF3,

m is selected from 1 and 2; and n is selected from 1, 2, and 3; or a pharmaceutically acceptable salt thereof.

10

20:

- 2. The compound according to claim 1, wherein $R^{\hat{I}}$ is selected
- from:
 (1) Gj-4alkyl,
 - (2) C3-10cycloalkyl-,
- 15 (3) cycloheteroalkyl,
 - (4) phenyl, and
 - (5) pyridyl,

wherein each alkyl is optionally substituted with one Ra substituent, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one to three substituents independently selected from Rb,

and pharmaceutically acceptable salts thereof.

- $\begin{tabular}{lll} \hline 3. & The compound according to any preceding claim, wherein R^2 is selected from$
- 25. R² is selected from:
 - (1) C₁₋₁₀alkyl,
 - (2) C3=10cycloalkyl,
 - (3) cycloheteroalkyl,
 - (4) aryl,
- 30: (5) heteroaryl,
 - (6) -ORd
 - (7) INRCRd
 - (8) -CO₂Rd, and

wherein each alkyl is optionally substituted with one, two or, three substituents independently selected from Ra, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one, two or three substitutents independently selected from Rb;

- 5 and pharmaceutically acceptable salts thereof.
 - 4. The compound according to claim 1, wherein:

R1 is selected from:

- (1) isopropyl,
- 10 (2) isobūtyl,
 - (3) n-propyl,
 - (4) cyclopropyl,
 - (5) cyclobutyl,
 - (6) cyclopentyl,
- 15 (7) cyclohexyl,
 - (8) piperidinyl,
 - (9) phenyl, and
 - (10) pyridyl,

wherein each alkyl is optionally substituted with one Ra substituent, and each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is optionally substituted with one to three substituents independently selected from Rb.

R2 is selected from:

- (1) cyclobutyl,
- (2) cyclopentyl,
- 25 (3) cycloliexyl,
 - (4) pyrrolidinyl,
 - (5) pyrimidinyl,
 - (6) benzoxazolyl,
 - (7) dihydroindolyl,
- 30 (8) dihydroquinolinyl,
 - (9) benzotriazolyl,
 - (10) thiophenyl,
 - (11) indolyl,
 - (12) indazolyl,
- 35 (13) pymolidinyl,


(14) pyridazinyl

	:(iS) triazolyl,
	(16) azaindolyl.
	(12) cyclobutylmethoxy;
5	(18) phenyl,
	(19) pyridyl,
	(20) -NRCRd, and
	(21) -CO2Rd
	wherein each alkyl is optionally substituted with one or two Ra substituents
10	and each phenyl or pyridyl is independently with one to three Rb substituents.
	R3 is methyl;
	R ⁴ is selected from hydrogen and methyl;
	R6 is selected from:
	(I) hydrogen,
15	(2) methyl,
	(3) hydroxyl,
	(4) halogen, and
	(5) -CN
*	A is selected from:
20	(1) benzódióxányl,
	(2) indanyl,
	(3) 1,2,3,4-tetrahydronaphthyl,
	(4) 6,7,8,9-tetrahydro[a][7]annulenyl,
	(5) chromanyl,
25	(6) 2,3-dihydrobenzyl furanyl,
	(7) 1,2,3,4-tetralnydroquinolinyl,
	(8) 4;2,3;4-tetrahydroisoquinolinyl;
	(9) 1,2,3,4-tetrahydro-1,4-quinazolinyl, and
	(î(i)) 1;2,3,4-tetrahydrocarbolinyl,
30	each optionally substituted with one, two, or three groups independently selected
	from Rbs
	each Rb is independently selected from:
	(1), methoxy,
100.00	(2) halôgen,
35°	SH,

- (4) -SCH₃,
- (5) -NH₂,
- (6) -C(O)CH₃,
- (7) -CO₂H,
- (8) -CO2CH3, .5
 - (9) -CF3,
 - (10) -OCF3
 - (11) C3-6-cycloalkyl,
 - (12) C1-4alkyl,
- 10 (13) phenyl,
 - (14) benzyl, and
 - (15) heteroaryl;

and pharmaceutically acceptable salts thereof.

5. A compound of structural formula IA;



(IA)

wherein:

RI is selected from:

20

15

- (1) aryl,
- (2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from Rb;

R² is selected from:

- 25
- (l) aryl,
- (2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from Rb;

R3 is selected from:

30

(1) C_{1.4}alkyl,

- (2) C2-4alkenyl,
- (3) C2-4alkynýl,
- (4) C3.7cycloalkyl;

wherein alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one; two, three or four substituents independently selected from Ra.

R4 is selected from:

5

- (1) hydrogen,
- (2) C₁₋₄alkyl,
- (3) C2-4alkenyl,
- 10 (4) C2-4alkynyl,
 - (5) -ORC,
 - (6) -CO2RC
 - (7) -OCORC
 - (8) -OCOORS
- 15 (9) -OCONRORG
 - (10) =NRdRe,
 - (11) -NH(CO)ORS,
 - (12) -NRCSO2RC
 - (13) -S(O)mRc
- 20 (14) aryl,

25

(15) heteroaryl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl, and cycloheteroalkyl are optionally substituted with one, two, three or four substituents independently selected from Ra, and aryl and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from Rb;

A is a 3- to 8-membered monocyclic saturated ring incorporating the same carbon atom to which R⁴ is attached and optionally containing one to two beteroatoms chosen from oxygen, mitrogen, and sulfur, and to which an arylor heteroaryl ring is fused, wherein said bicyclic ring is optionally fused to another aryl or heteroaryl ring to form a tricyclic ring wherein the A ring system is optionally substituted with one; two, three or four substituents selected from a group independently selected from oxo and R^b;

each Ra is independently selected from:

(1) ORd,

TO THE STATE OF TH

- (2) -NRCS(O)mRd, -NO2, (3) (4) halogen, $(5) -S(O)_{m}R^{\circ}$ 5 (6) -SRc, (7) $-S(O)_2OR^c$, (8) -S(O)mNRCRd, (9) -NRCRd, (10) -O(ERerf)nNRCRd, 10 (11) -C(O)RC (12) -CO2RC, (13) -CO2(CReRI)nCONRORd, (14) -OC(O)RC, (15) -CN, (16) -C(O)NRCRd. 15 (17) -NRC(O)Rd, (18) -OC(O)NRCRd, (19) -NRCC(O)ORd, (20) -NRCC(O)NRCRd, (21) -CRC(N-ORd), 20 (22) CF3, (23) ~OCF3, (24) -C3-8cycloalkyl, and (25) cycloheteroalkyl; each Rb is independently selected from: 25 (1) \mathbb{R}^{a} , (2) C₁₋₁₀alkyl,
 - (3) aryl, (4) arylC₁.4alkyl,
- 30 (5) heteroaryl, and (6) heteroarylC124alkyl;
 - RS and Rd are independently selected from
 - (1) hydrogen,
 - (2) C₁-10alkyl,

- (3) C2-10 alkenyl,
- (4) C2-10alkynyl,
- (5) cycloalkyl,
- (6) cycloalkyl-C1-10alkyl;
- 5

- (7) cycloheteroalkyl,
- (8) cycloheteroalkyl-C1-10 alkyl;
- (9) aryl,
- (10) heteroaryl.
- (11) aryl-C[=[0alkyl, and
- 10 (12) lieteroaryl-C1-10alkyl, or

Rc and Rd together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and NaRs,

each RC and Rd may be unsubstituted or substituted on a carbon or nitrogen atom with one, two or three substituents selected from Rh.

Re and Rf are independently selected from hydrogen, C1-10alkyl, G2-10alkenyl, C2-10alkynyl, cycloalkyl, cycloalkyl-C1-10alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-10alkyl, aryl, heteroaryl, aryl-C1-10alkyl, and heteroaryl-C1-10alkyl, or

Re and R together with the carbon to which they are attached form a ring of 5 to 7 members containing 0; 1, or 2 heteroatoms independently selected from oxygen; sulfur and nitrogen;

each Rg is independently selected from

- (1) hydrogen,
- (2) C1-10alkyl,
- 25 (3) C3-scycloalkyl,
 - (4) heterocycloalkyl,
 - (5) aryi,
 - (6) arylC₁-4alkyl,
 - (7) heteroaryl;
- 30 (8) heteroarylC₁-4alkyl,
 - (9) $-S(O)_{m}R^{c}$
 - (10) -C(O)RC
 - (11) -CO2RC,
 - (12) CO2(CRCRI) CONRCRI and

ANT 3A APROT

(13) -C(0)NRcRd; each Rh is independently selected from: (l) halogen, (2) C₁₋₁₀alkyl, (3) C3-8cycloalkyl, 5 (4) heterocycloalkyl, (5) aryl, (6) arylC1-4alkyl, (7) heteroaryl, heteroarylC1-4alkyl. 10 (9) -ORC, (10) -NRCS(O)mRd, (11) -S(O)mRc; (12) -SRC, (13) -S(0)20Rc. 15 (14) -S(0)mNRcRd, (15) -NRCRd, (16) O(CRERI) NRORD, (17) -C(O)Rc. (18) -CO2RC, 20 (19) -CO2(CR\$Rf)nCONR\$Rd, (20) -OC(O)RC, (21) -CN, (22) -C(O)NRCRd, (23) -NR¢Ć(O)Rd, 25 (24) -OC(O)NRCRd (25) -NRCC(O)ORd, (26) -NRCC(O)NRCRd, (27) CF3, and

m is selected from 1 and 2; and nits selected from 1, 2, and 3; or a pharmaceutically acceptable salt thereof:

(28) -OCF3,

6. The compound according to any one of claims 1 to 3 or 5, wherein R⁴ is selected from:

Compression de l'argent de

- (1) hydrogen,
- (2) C1-4alkyl, and
- (3) cyclopropyl,
 wherein alkyl and cyclopropyl are optionally substituted with one, two or three Ra substituents;

and pharmaceutically acceptable salts thereof.

- The compound according to any one of claims 1 to 3; 5 or 6, wherein R³ is selected from
 - (1) methyl,
 - (2) trifluoromethyl, and
 - (3) cyclopropyl,
- and pharmaceutically acceptable salts thereof
 - The compound according to any preceding claim, wherein R1 is selected from
 - (1) phenyl, and
- 20 (2) pyridyl,

30

wherein phenyl and pyridyl are optionally substituted with one or two Rb substituents.

and pharmaceutically acceptable salts thereof

- 25 9. The compound according to any preceding claim, wherein R2 is selected from:
 - (1) phenyl, and
 - (2) pyridyl;

wherein phenyl and pyridyl are optionally substituted with one or two Rb substituents.

and pharmaceutically acceptable salts thereof

The compound according to any one of claims 1 to 3 or 5 to 9, wherein A is a cyclopentyl, cyclohexyl, cycloheptyl, dioxanyl, tetrahydrofuranyl, or oxanyl, ring fused to a phenyl, or pyrrolyl ring, optionally fused to a phenyl ring to

- 178 -

AFT 3A ANNOT

form a tricyclic ring wherein the A ring system is optionally substituted with one, two or three Rb substituents;

and pharmaceutically acceptable salts thereof.

5. The compound according to Claim-5, wherein:

 \mathbf{R}^{T} is selected from phenyl and 4-chlorophenyl;

R2 is selected from:

- (1) phenyl, and
- (2) pyridyl,
- wherein phenyl and pyridyl are optionally substituted with one or two halogen substituents;

R3 is methyl;

R4 is selected from hydrogen and methyl,

A is selected from:

- (1) benzodioxanyl,
 - (2) indanyl,
 - (3) 1,2,3,4 tetrahydronaphthyl,
 - (4) 6,7,8,9-tetrahydro[a][7]annuleny],
 - (5) chromanyl,
- 20 (6) 2;3:dihydrobenzyl füranyl,
 - (7) 1,2,3,4-tetrahydroguinolinyl,
 - (8) 1,2,3,4-tetrahydroisoquinolinyl,
 - (9) 1,2,3,4-tetrahydro-1,4-quinazolinyl, and
 - (10) 1,2,3,4-tetrahydrocarbolinyl,
- each optionally substituted with one, two of three groups independently selected from Rb.

each Rb is independently selected from:

- (i) methoxy,
- (2) halogen,
- 30 (3) -SH,
 - (4) -SCH₃;
 - AND SOM
 - (5) -NH₂,
 - (6) -C(0)CH3,
 - (7) -CO₂H₂
- 35 (8) -CO2CH3,

⊵-ii70⇔

ART 34 ALTOT

- (9) -CF3
- (10) -OCF3.
- (11) C3-6 cycloalkyl,
- (12) C1-4alkyl,
- 5 (13) phenyl,
 - (14) benzyl, and
 - (15) heteroaryl;

and pharmaceutically acceptable salts thereof.

- 10 12. The compound according to claim 1, selected from:
 - (1) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide;

- (2) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-indano-1-carboxamide;
- (3) N-(2,3-bis(4-clilorophenyl)-1-methylpropyl)-2,3-dihydrobenzofuran-2-carboxamide.
- 15 (4) *N*=(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1-2,3,4-tetrahydrocarbazote-1-carboxamide,
 - (5) N=[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide,
 - (6) N=[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2-carboxamide.
- 20 (7) N-[2,3-bis(4-chlorophenyl)-1-methypropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide,
 - (8) N-[3:(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2;3-dihydrobenzofuran-2-carboxamide,
- (9) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide,
 - (10) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-1;2,3;4-tetrahydro-2-naphthamide;
 - (E1) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide,
- 30 (12) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-2-carboxamide,
 - (13) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-2-carboxamide,
 - (14) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide,

20

(15) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-2carboxamide,

- (16) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]chromane-3-carboxamide.
- (17) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-3-carboxamide,
- (18) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-methylchromane-3carboxamide,
 - (19) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-3-methylchromane-3carboxamide,
 - (20) N-[2,3-bis(4-chlorophenyi)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4benzodioxane-2-carboxamide;
 - (21) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4benzodioxane-2-carboxamide,
 - (22) N=[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2carboxamide,
- 15 (23) N=[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4benzodioxane-2-carboxamide;
 - (24) N-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4benzodioxane-2-carboxamide;
 - (25) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5Hbenzo[a][7]annulene-6-carboxamide,
 - (26) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5Hbenzo[a][7]annulene-6-carboxamide,
 - (27) N-[2,3-bis(4-chlorophenyl)-1-methypropyl]-6,7,8,9-tetrahydro-5Hbenzo[a][7]annulene-7-carboxamide,
- 25 (28) N-[3-(4-chlorophenýl)-1-methý-2-phenylpropyl]-6,7.8,9-tetrahydro-5Hbenzo[a][7]annulene-7-carboxamide,
 - (29) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2;3-dihydro-1,4benzodioxane-2-carboxamide.
- (30) N-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-30 benzodioxane-2-carboxamide,
 - (31) N-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-3-methylchromane-3carboxamide,
 - (32) N-[3-(4-chlorophenyl)=2(S)-phenyl-I(S)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide. ART 34 ANDT

 $(33): \ \textit{N-}[3^{\circ}(4\text{-chlorophenyl})-2(S)-phenyl-1(S)-methylpropyl]-6\text{-chloro-}2\text{-methyl-}2;3-methylpropyl-1(S)-m$ dihydro-1,4-benzodioxane-2-carboxamide,

os yakiya mosahirika o di sasmoo

- (34) N-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-7-chloro-2-methyl-2/3dihydro-1,4-benzodioxane-2-carboxamide;
- -53 and pharmaceutically acceptable salts thereof.

13., The compound according to claim 1, selected from:

- (1) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzôdioxane-2-carboxamide,
- (2) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-indane-1-carboxamide,
- 10 (3) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-2,3-dilydrobenzofuran-2carboxamide.
 - N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,2,3,4-tetrahydrocarbazole-1-(4) carboxamide,
- (5) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetraliydro-2-naphthamide, 15 diastereomer I,
 - (6) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide, diastereomer II.
 - (7) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetraliydro-2-naphthamide; diastereomer III,
- 20 (8) N-[2,3]-bis(4-chlorophenyl)-1-methylpropyl]-1,2,3,4-tetrahydro-2-naphthamide, diastercomer IV,
 - (9) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2carboxamide diastereomer 1,
- (10) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2-25 carboxamide diastereonier II;
 - (11) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydrobenzofuran-2carboxamide, diastereomers I and II (I-II),
 - (12) N-[2,3-bis(4-chlorophenyl)-1-methypropyl]-2-methyl-2,3-dihydrobenzofuran-2 carboxamide diastereomer I,
- (13) N-[2,3-bis(4-chlorophenyl)-1-methypropyl]-2-methyl-2,3-dihydrobenzofuran-2-30 carboxamide diastereomer II,
 - (14) N-[2/3-bis(4-chlorophenyl) 1-methypropyl] 2-methyl-2, 3-dihydrobenzofuran-2carboxamide, diastereomers I and II (1:1),
- (15) N=[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2;3-35 dihydrobenzofuran-2-carboxamide:diastereomer I,

20

30.

- (16) N:[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]=2-methyl-2,3-dihydrobenzofuran-2-carboxamide diastercomer II.
- (1.7) N₂[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydrobenzofuran-2-carboxamide, diastereoniers I and II.(1:1),
- 5 (18) W.[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide diastereomer l,
 - (19) N-[2;3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide, diastercomer II,
 - (20) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-1,2,3,4-tetrahydro-2-naphthamide diastercomers I and II (1:1).
 - (21) N-[3-(4-chlorophenyl)-1-metliy-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide diastereomer I,
 - (22) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-1,2,3,4-tetrahydro-2-naphthamide:diastereomer II,
- 15 (23) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-1;2;3,4-tetrahydro-2-naphthamide diastereomers Land II (1-1);
 - (24) N-[2,3] bis(4-chlorophenyl)-1-methylpropyl]chromane-2-carboxamide diastereomers I and H (1.1);
 - (25) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-2-carboxamide diastereomers Land II (4:1),
 - (26) N-[2;3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomer is
 - (27) N [2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomer II.
- 25. (28) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methylchromane-2-carboxamide diastereomers I and II (1:1).
 - (29) N-[3-(4-chiloropheny])-1-methy-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomer l.
 - (30) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-2-carboxamide diastereomer II.
 - (31) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methylchromane-2carboxamide diastereomers I and II (1:1),
 - (32) N-[2:3-bis(4-chilorophenyl)-1-methylpropyl]chromane-3-carboxamide diastereomers I and II (4:1).

ART 34 AMOST

20

30

- (33) *N*-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]chromane-3-carboxamide diastereomers F and II; (1:1),
- (34) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-methylchromane-3-carboxamide diastereomers Land II (1:1).

AND WAR SERVING THE SERVING THE SERVING TO SERVING THE SERVING THE

- 5 (35) W-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-3-methylchromane-3carboxamide diastereomers I and II (1:1).
 - (36) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I,
 - (37) N²[2,3-bis(4-chlorophenyl)-I-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II,
 - (38) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2,3-diliydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1),
 - (39) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer l,
- 15 (40) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4benzodioxane-2-carboxamide diastercomer II;
 - (41) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1).
 - (42) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide, diastereomer III,
 - (43) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer IV₃.
 - (44) N=[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereoner I,
- 25 (45) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2,3-dihydro-1,4-benzodioxane-2-carboxamide-diastereomer II,
 - (46) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2.3-dihydro-1.4-benzodioxane-2-carboxamide diastereomers Land II (1:1).
 - (47) N-[3-(4-chlorophényl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4henzodioxane-2-carboxamide diastereomers I and II (3:1),
 - (48) W-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomers I and II (1:1);
 - (49) N-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2-3-dihydro-1,4-benzodioxane-2-carboxamide-diastereomer II,

DAL 30 breeze

20.

- (50) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5H-benzo[a][7]annulene-6-carboxamide diastercomer I,
- (51) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-6-carboxamide diaster-comer II;
- 5 (52) N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-6,7,8,9-tetrahydro-5H: benzo[a][7]annulene-6-carboxamide diastercomers I and II-(1-1),
 - (53) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5H-benzo[a][7]annulene-6-carboxamide diastercomer I,
 - (54). N-[3-(4-chlorophenyl)-1-melhy-2-phenylpropyl]-6,7,8,9-tetrahydro-5//-benzo[a][7]annulene-6-carboxamide diastereomer II;
 - (55) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5H-benzo[a][7]annulene-6-carboxamide diastereomers I and H (1-1).
 - (56) N-[2,3-b)s(4-chlorophenyl)-1-methypropyl]-6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulene-7-carboxamide diastereomers-1-and-H₂(1:1),
- 15 (57) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-6,7,8,9-tetrahydro-5H-benzo[a][7]annulene-7-carboxamide diastercomers I and II (151).
 - (58) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastercomer l'enantiomer A,
 - (59) N-[3-(4-chlorophenyl)-1-methy-2-phenylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer llenantiomer B,
 - (60) N-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer i, enantiomer A₃
 - (61) N-[3-(4-chlorophenyl)-1-methy-3-pyridylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I₂-enantiomer B₃
- 25 (62) N-[3-(4-chlorophenyl)-2(\$)-phenyl-1(\$)-methylpropyll-3-methylchromane-3carboxamide diastercomer/L
 - (63) N-[3-(4-chlorophenyl)=2(S)-phenyl=1(S)-methylpropyl]-3-methylchromane-3-carboxamide.dias(ercomer-II,
 - (64) N-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer I.
 - (65): N-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-2-methyl-2,3-dihydro-L4-benzodioxane-2-carboxamide diastercomer.H.
 - (66): N-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-6-chloro-2-methyl-2/3-dihydro-1/4-benzodioxane-2-carboxamide-diastercomer 1.



- (67) N:[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-7-chloro-2-methyl-2;3-dihydro-1;4-benzodioxane-2-carboxamide diastercomer i;
- (68) N-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-6-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastercomer II,
- 5 (69) N-[3-(4-chlorophenyl)-2(S)-phenyl-1(S)-methylpropyl]-7-chloro-2-methyl-2,3-dihydro-1,4-benzodioxane-2-carboxamide diastereomer II, and pharmaceutically acceptable salts thereof.
- 14. A pharmaceutical composition comprising a compound according to any preceding claim, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
 - A compound according to any one of claims I to 13, or a pharmaceutically acceptable salt thereof for use in therapy.
 - The use of a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease mediated by the Cannabinoid-I receptor.
- The use according to claim 16 wherein the disease mediated by the Cannabinoid-1 receptor is selected from: psychosis, memory deficit, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorders, constipation, chronic intestinal pseudo-obstruction, circhosis of the liver, asthma, obesity, and other eating disorders associated with excessive food intake:
- 18. The use according to claim 17, wherein the eating disorder associated with excessive food intake is selected from obesity, bulimia nervosa, and compulsive eating disorders.



This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

□ OTHER: _____

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.